Indications
Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).
Composition
- Active substance
- Damoctocog alfa pegol
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jivi
- Active substance
- Damoctocog alfa pegol
- ATC code
- B02BD02
- Therapeutic area
- Hemophilia A
- Marketing authorisation holder
- Bayer AG
- Status
- Authorised
- EU authorisation
- 22 Nov 2018